Ublituximab, a novel antibody , represents a significant development in the approach of inflammatory conditions. Differing from many current therapies, ublituximab selectively targets and reduces B cells, https://emab-6244747.blog5.net/95977804/ublituximab-a-fresh-promise-for-autoimmune-conditions